BioTuesdays

Category - Markets

Cascadian Therapeutics
Markets

BTIG starts Cascadian at buy

BTIG initiated coverage of Cascadian Therapeutics (NASDAQ:CASC) with a “buy” rating and $13 price target. The stock closed at $3.92 On April 20. Cascadian is focused on the development of Tucatinib, an oral, highly...

April 21, 2017
Zafgen Logo
Markets

Roth starts Zafgen at buy

Roth Capital Partners launched coverage of Zafgen (NASDAQ:ZFGN) with a “buy” rating and $9 price target. The stock closed at $4.90 on April 19. “We expect a number of events over the coming 12 months to drive investor...

April 20, 2017
Poxel
Markets

Roth starts Poxel SA at buy

Roth Capital Partners initiated coverage of Poxel SA (NXT:PA) with a “buy” rating and price target of €11. The stock was recently quoted at €5.14. Poxel’s Imeglimin has demonstrated promising efficacy for the treatment...

April 20, 2017
Mateon Therapeutics
Markets

Roth starts Mateon at buy

Roth Capital Markets launched coverage on Mateon Therapeutics (OTCQX:MATN) with a “buy” rating and $2 price target. The stock closed at 77 cents on April 19. “Following positive results from a randomized Phase 2 study...

April 20, 2017
Theratechnologies
Markets

CIBC starts Theratechnologies at OP

CIBC World Markets initiated coverage of Theratechnologies (TSX:TH) with an “outperform” rating and $10 price target. The stock closed at $5.95 on April 19. Theratechnologies has a focused strategy and business plan to...

April 20, 2017
ImmunoGen
Markets

Leerink ups Immunogen to OP from MP

Leerink upgraded Immunogen (NASDAQ:IMGN) to “outperform” from “market perform” and raised its price target to $8 from $2 based on a “higher level of conviction” on lead asset, mirvetuximab soravtansine, providing an...

April 19, 2017
Quotient
Markets

BTIG starts Quotient at buy

BTIG initiated coverage of Quotient (NASDAQ:QTNT) with a “buy” rating and $22 price target. The stock closed at $6.26 on April 17. British-based Quotient develops and commercializes tests for blood grouping and...

April 18, 2017
Bellerophon Therapeutics
Markets

Ladenburg starts Bellerophon at buy

Ladenburg Thalmann initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and 12-month price target of $4.50. The stock closed at $1.18 on April 13. Bellerophon is developing and optimizing...

April 17, 2017
Reata Pharma
Markets

Ladenburg starts Reata at buy

Ladenburg Thalmann launched coverage of Reata Pharmaceuticals (NASDAQ:RETA) with a “buy” rating and price target of $55. The stock closed at $21.21 on April 12. Reata focuses on development of small molecule drugs for...

April 13, 2017
Auris Medical
Markets

Roth starts Auris Medical at buy

Roth Capital Partners initiated coverage of Auris Medical Holding (NASDAQ:EARS), a Swiss biopharmaceutical company developing therapeutics that address unmet medical needs in otology, with a “buy” rating and price...

April 13, 2017